

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-18 (Cancelled)

Claim 19 (Previously Presented) A pharmaceutical composition comprising a growth blocking agent according to claim 21 and a pharmaceutically acceptable carrier or diluent.

Claim 20 (Cancelled)

Claim 21 (Presently Amended) An isolated growth blocking agent that binds to a vitamin B<sub>12</sub> binding site on TcII, ~~said agent being capable of competitively antagonizing or modulating said binding site to~~ wherein said agent inhibits the cellular uptake of vitamin B<sub>12</sub>, and wherein said agent is a monoclonal antibody.

Claim 22 (New) A monoclonal antibody that binds to TcII, wherein said monoclonal antibody inhibits the binding of vitamin B<sub>12</sub> to TcII, inhibits cellular uptake of vitamin B<sub>12</sub>, and blocks cell growth.

Claim 23 (New) A pharmaceutical composition comprising the monoclonal antibody of claim 22 and a pharmaceutically acceptable carrier or diluent.